Publications by authors named "David D Darr"

Claim this Profile
P
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
John E Bisi, Jessica A Sorrentino, Jamie L Jordan, David D Darr, Patrick J Roberts

Oncotargetยท June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis